UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 18, 2013
pSivida Corp.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-51122 | | 26-2774444 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
| 400 Pleasant Street, Watertown, MA | | 02472 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (617) 826-5000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On December 18, 2013, pSivida Corp., a Delaware corporation (“pSivida”) issued a press release announcing that its licensee, Alimera Sciences, Inc., has entered into labeling discussions with the U.S. Food and Drug Administration (the “FDA”) for ILUVIEN® for Diabetic Macular Edema (“DME”) and, as a result, reported its agreement with the FDA that the January 2014 Dermatologic and Ophthalmic Advisory Committee meeting to discuss ILUVIEN for DME was no longer necessary.
pSivida’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press Release of pSivida dated December 18, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
December 19, 2013
| | |
| PSIVIDA CORP. |
|
/s/ Lori Freedman |
| Name: | | Lori Freedman |
| Title: | | Vice President Corporate Affairs, General Counsel and Secretary |
Exhibit Index
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press Release of pSivida dated December 18, 2013 |
